117m Sn DTPA

Drug Profile

117m Sn DTPA

Alternative Names: Pentetate 117m Sn; Stanamet; Tin-117m DTPA

Latest Information Update: 05 Jun 2007

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Bayer Schering Pharma; Nonindustrial source
  • Class Analgesics; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Bone cancer; Cancer pain

Most Recent Events

  • 17 Jun 2004 Discontinued - Phase-II for Cancer pain in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
  • 01 Jul 1999 The US Department of Energy will give Brookhaven National Laboratory US$750,000 over 3 years to develop Stanamet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top